Edition:
United States

North China Pharmaceutical Co Ltd (600812.SS)

600812.SS on Shanghai Stock Exchange

5.97CNY
10:42pm EDT
Change (% chg)

¥-0.01 (-0.17%)
Prev Close
¥5.98
Open
¥5.95
Day's High
¥5.98
Day's Low
¥5.92
Volume
4,525,602
Avg. Vol
10,552,116
52-wk High
¥7.60
52-wk Low
¥5.90

600812.SS

Chart for 600812.SS

About

North China Pharmaceutical Company. Ltd is a China-based company principally engaged in the production and distribution of pharmaceuticals. The Company's main products are classified as penicillin, cephalosporin, vitamin and other products, including bulk pharmaceuticals, finish preparations and healthcare products, among... (more)
No analyst recommendations are available for 600812.SS.

Overall

Beta: 1.03
Market Cap(Mil.): ¥9,654.36
Shares Outstanding(Mil.): 1,630.81
Dividend: 0.02
Yield (%): 0.34

Financials

  600812.SS Industry Sector
P/E (TTM): 178.69 29.15 30.10
EPS (TTM): 0.03 -- --
ROI: 0.69 13.65 13.21
ROE: 1.02 14.61 14.37

BRIEF-North China Pharmaceutical unit gets Certificate of Suitability to Monograph of European Pharmacopoeia

* Says wholly owned unit received Certificate of Suitability to Monograph of European Pharmacopoeia, from European Directorate for Quality of Medicines & HealthCare, for AMOXICILLIN TRIHYDRATE

Apr 16 2017

BRIEF-Lock-up period for North China Pharma's 252.2 mln shares to end

* Says lock-up period for 252.2 million shares to end, shares to start trading on April 10

Apr 02 2017

BRIEF-North China Pharmaceutical receives GMP certificate

* Says it received goods manufacture practice(GMP) certificate from Hebei Food and Drug Administration on March 21

Mar 22 2017

BRIEF-North China Pharma's chairman resigns due to personal reasons

* Says its Chairman Guo Zhouke resigns due to personal reasons

Feb 09 2017

BRIEF-North China Pharmaceutical unit receives GMP certificate

* Says its wholly owned pharma unit received goods manufacture practice (GMP) certificate from Hebei Food and Drug Administration on Jan. 6

Jan 08 2017

BRIEF-North China Pharma plans to issue debt financing instruments

* Says it plans to issue up to 2.0 billion yuan ($290.00 million) debt financing instruments

Nov 23 2016

BRIEF-North China Pharmaceutical and units ordered to halt production to tackle pollution

* Says it and four units in Shijiazhuang are ordered to halt production by local government as part of government efforts to tackle pollution

Nov 21 2016

BRIEF-North China Pharmaceutical gets approval for clinical trial

* Says it received approval from Food and Drug Administration Bureau on Oct. 25 for clinical trial of capecitabine tablets

Oct 26 2016

More From Around the Web

Earnings vs. Estimates